IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Seneca House Advisors

Seneca House Advisors lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 916 shares of the company’s stock after selling 48 shares during the quarter. Seneca House Advisors’ holdings in IDEXX Laboratories were worth $379,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Frank Rimerman Advisors LLC purchased a new position in IDEXX Laboratories during the 2nd quarter valued at about $253,000. Public Sector Pension Investment Board lifted its position in shares of IDEXX Laboratories by 67.6% during the second quarter. Public Sector Pension Investment Board now owns 3,078 shares of the company’s stock worth $1,500,000 after purchasing an additional 1,241 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of IDEXX Laboratories by 2.5% in the second quarter. Marshall Wace LLP now owns 20,500 shares of the company’s stock valued at $9,988,000 after purchasing an additional 500 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of IDEXX Laboratories by 60.5% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 15,914 shares of the company’s stock valued at $7,753,000 after purchasing an additional 5,998 shares in the last quarter. Finally, APG Asset Management US Inc. grew its holdings in shares of IDEXX Laboratories by 10.8% in the second quarter. APG Asset Management US Inc. now owns 52,577 shares of the company’s stock valued at $25,048,000 after purchasing an additional 5,139 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $432.34 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The firm has a market capitalization of $35.40 billion, a P/E ratio of 41.69, a PEG ratio of 3.63 and a beta of 1.36. The company’s fifty day moving average is $423.28 and its two-hundred day moving average is $456.85.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.53 earnings per share. Analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Barclays reduced their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Piper Sandler reiterated a “neutral” rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $523.86.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.11% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.